FDA: Merck’s sleep drug suvorexant effective, but safety issues draw heavy flak
More death merchant peddling from MERCK in the attached article (“Mostly Evil Researchers Crooks and Kafkaesquers” as described by a former MERCK Senior Vice President).
Want real proven wellness?
GOT ZIJA SUPERMIX?!
~ Uncle Russ
FDA staffers found clear evidence to prove that Merck’s blockbuster drug candidate suvorexant is quite effective in promoting sleep, but the internal review cites multiple safety issues for the high doses studied in clinical trials. And agency staffers are asking an upcoming meeting of FDA experts to determine whether or not patients should be started off on an even lower dose of the insomnia drug than Merck ($MRK) is seeking an approval on.